Home - Auvega LABS Inc. GENERALS

PIONEERING A NEW ASSET CLASS IN HEALTH

Invest In The Future Of Psychedelic Medicine

A PORTFOLIO OF MARKET INNOVATING VENTURES

We’re proud to offer a large range of portfolios of integrated wellness assets in alternative medicine, supplements, and psychedelic pharmacology.

CREATED BY LEADERS FOR LEADERS

Directed by the world’s leading experts in psychedelic treatment, Auvega’s scientific advisory board is currently engaging leading universities and research teams.

WORLD-CHANGING IDEAS

Auvega is powered by innovation and exploring new and emergent markets in alternative medicine, supplements, and psychedelic pharmacology.

PREMIUM PLANT BASED SUPPLEMENTATION​

Wellness Assets to fund advancements in Alternative Medicine, Supplements, and Psychedelic Pharmacology. ​

A PSYCHOACTIVE MEDICINE RENAISSANCE

322M

people suffer from depression worldwide

300M

people suffer from PTSD worldwide

164M

people suffer from substance abuse worldwide

1 in 5

American adults suffer from a form of mental illness

30.6%

of people affected by mass conflicts have PTSD

493%

increase in OUD diagnosis in the U.S. from 2010-2016

$1T

the estimated cost of depression to the global economy

$6T

estimated global cost of mental health conditions in 2030 by the World Economic Forum(up from $2.5 trillion in 2010)

115

people die every day from opioid abuse

RECENT PSYCHEDELIC TIMELINE

Over 7000 Years in the making

2020 – Jan

Santa Cruz, California decriminalized the cultivation and possession of psilocybin mushrooms, ayahuasca, peyote, and ibogaine.

2020-March

MindMed begin trading on the NEO Exchange under the symbol NEO:MMED. It was the world’s first publicly traded psychedelic pharmaceutical company.

2020 – Aug

Canadian Health Minister Patty Hajdu approved the use of psilocybin mushrooms for four people with incurable cancer. This was the first time that an exemption to the Controlled Drugs and Substances Act has been granted for the use of mushrooms.

2020 – Sep

Ann Arbor, Michigan became the third city in the United States to decriminalize all naturally-occurring psychedelic plants and fungi.

2020 – Oct

Canada Numinus Wellness Inc. harvested the first legal flush of psilocybin mushrooms by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s License.

2020 – Nov

Washington, D.C. decriminalized the possession and cultivation of psychedelic plants and fungi. Oregon legalized psilocybin for the mental health treatment of adults in supervised settings. It also decriminalized the possession of small amounts of street drugs, including psychedelics.

SUPPORTING & EMPOWERING THE JOURNEY TO WELLNESS.

Special Access for psilocybin & MDMA

Pending approval of regulatory change, Auvega Labs Inc. intends to support practitioners in helping their patients obtain Special Access to psychedelic-assisted therapies for a range of conditions and delivering these through the clinics.

Health Canada has posted its Notice of Intent, subject to public consultation, to revise its Special Access Program to allow legal access to psilocybin and MDMA outside clinical trials, while the substances await formal approvals.

Auvega Labs Inc. supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of the healthcare system.

In The News